AstraZeneca and thrombosis, in Italy one case every 100 thousand doses

One case of thrombosis for every 100,000 doses of AstraZeneca vaccine. No cases after the second dose of the vaccine, currently recommended in Italy for people over 60 and back in the spotlight after 2 cases of thrombosis in younger patients. Given the numerous Open Days, the vaccine was also administered to subjects under the age of 60. The reporting rate of intracranial and atypical venous thrombosis in subjects vaccinated with AstraZeneca’s anti-Covid Vaxzevria vaccine “is in line with what has been observed at the European level”. This is “1 case for every 100,000 first doses administered” and “no cases after the second dose”, emerges from the fifth Pharmacovigilance Report on Covid-19 vaccines, published by the Italian drug agency Aifa. Read also These rare adverse events were reported “mainly in people under the age of 60”, is confirmed in the report, which contains data on reports of suspected adverse reactions registered in the National Pharmacovigilance Network between 27 December 2020 and 26 May 2021 for the 4 vaccines in use in the current vaccination campaign. Between 27 December 2020 and 26 May 2021, for the 4 vaccines in use in the ongoing anti-Covid vaccination campaign, 66,258 adverse reaction reports were received out of a total of 32,429 .611 doses administered (reporting rate of 204 per 100 thousand doses), of which approximately 90% refer to non-serious events such as pain at the injection site, fever, asthenia / fatigue, muscle aches. The reactions reported – the report reads – arise mainly on the same day of vaccination or the next day (83% of cases). Serious reports correspond to 10.4% of the total, with a rate of 21 serious events per 100 thousand doses administered, regardless of the type of vaccine, the dose (first or second) and the possible causal role of vaccination. relate to the Pfizer vaccine (71.8%), so far the most used in the vaccination campaign (68.7% of the doses administered) and only to a lesser extent to AstraZeneca’s Vaxzevria vaccine (24% of reports and 20.8% of doses administered), Moderna vaccine (3.9% of reports and 9% of administered doses) and Johnson & Johnson vaccine (0.3% of reports and 1.5% of administered doses). For all vaccines – it is specified in the Aifa report – the most reported adverse events are fever, fatigue, headache, muscle / joint pain, pain at the injection site, chills and nausea. flu-like syndrome with intense symptoms, more frequent after the second dose of mRna vaccines and after the first dose of Vaxzevria.